1. Academic Validation
  2. Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury

Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury

  • J Neuroinflammation. 2016 Aug 22;13(1):192. doi: 10.1186/s12974-016-0660-1.
Po Wang 1 2 Yating He 1 Daojing Li 1 Ranran Han 1 Guiyou Liu 3 Dexin Kong 4 Junwei Hao 5 6
Affiliations

Affiliations

  • 1 Department of Neurology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
  • 2 Department of Neurology, Baotou Central Hospital, Baotou, Inner Mongolia, 014000, China.
  • 3 Genome Analysis Laboratory, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, 300000, China.
  • 4 Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
  • 5 Department of Neurology, Tianjin Medical University General Hospital, Tianjin, 300052, China. [email protected].
  • 6 Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, 300052, China. [email protected].
Abstract

Background: Microglia/macrophages play a critical role in the inflammatory and immune processes of cerebral ischemia/reperfusion injury. Since microglia/macrophages can reversibly shift their phenotype toward either a "detrimental" or a "restorative" state in the injured central nervous system (CNS), compounds mediate that shift which could inhibit inflammation and restore the ability to alleviate cerebral ischemia/reperfusion injury would have therapeutic potential.

Methods: Transient middle cerebral artery occlusion was induced in male C57BL/6 mice. Mice were randomly separated into a sham-operated group, a control group, and a ZSTK474-treated group. We investigated the effect of ZSTK474 by assessing neurological deficits, infarct volume, and histopathological changes. We then determined the potential mechanism by immunofluorescent staining, quantitative real-time polymerase chain reaction (PCR), and Western blot analysis. The Tukey's test or Mann-Whitney U test was used to compare differences among the groups.

Results: ZSTK474 alleviated neurological deficits and reduced infarct volume in the cerebral ischemia/reperfusion injury model. Presumably, ZSTK474 shifted the phenotype of microglia/macrophages to a restorative state, since this treatment decreased the secretion of pro-inflammatory factors and advanced the secretion of anti-inflammatory factors. These neuroprotective properties of ZSTK474 may be mediated by the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin complex 1 (mTORC1) pathway.

Conclusions: ZSTK474 can mediate a shift in microglia/macrophage phenotype and inhibit the inflammatory response in cerebral ischemia reperfusion injury of mice. These effects appeared to ensue via the PI3K/Akt/mTORC1 pathway. Therefore, ZSTK474 may represent a therapeutic intervention with potential for circumventing the catastrophic aftermath of ischemic stroke.

Keywords

Cerebral ischemia reperfusion injury; Inflammation; Microglia/macrophages; PI3K/AKT/mTORC1 pathway; ZSTK474.

Figures
Products